Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
Dihydroergotamine mesylate (DHE) has been used in migraine therapy since the 1940s. Renewed interest in its use has been kindled by research in receptor pharmacology and by efficacy of DHE-45 in breaking the cycle of chronic daily headache. Nasal and oral routes of administration may widen the applicability of DHE.